We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$117M
Cap. Flow
+$131M
Cap. Flow %
33.06%
Top 10 Hldgs %
59.9%
Holding
91
New
22
Increased
27
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.78M
2
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$6.98M
3
OCUL icon
Ocular Therapeutix
OCUL
+$5.62M
4
BBIO icon
BridgeBio Pharma
BBIO
+$5.6M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.42M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$6.29M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.74M
3
XLRN
Acceleron Pharma
XLRN
+$2.57M
4
MGNX icon
MacroGenics
MGNX
+$2.15M
5
EPIX
ESSA Pharma
EPIX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 55.88%
2 Financials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
26
DELISTED
NanoString Technologies, Inc.
NSTG
$3.6M 0.91%
75,000
+60,000
+400% +$3.45M
TRIL
27
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.51M 0.89%
+200,000
New +$2.34M
CNTA
28
DELISTED
Centessa Pharmaceuticals
CNTA
$3.39M 0.86%
203,183
+136,226
+203% +$2.82M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$3.27M 0.83%
532,030
+232,030
+77% +$880K
RFL icon
30
PUT
Rafael Holdings
RFL
$112M
$3.11M 0.79%
+102,617
New +$4.71M
PRCT icon
31
Procept Biorobotics
PRCT
$1.08B
$3M 0.76%
+78,534
New +$3.01M
OBIO icon
32
Orchestra BioMed
OBIO
$222M
$2.97M 0.75%
300,000
– –
GRNA
33
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$2.97M 0.75%
+300,000
New +$2.94M
MSAC
34
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.92M 0.74%
300,000
– –
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$377M
$2.4M 0.61%
80,228
-39,772
-33% -$1.45M
CLDX icon
36
Celldex Therapeutics
CLDX
$2.77B
$2.17M 0.55%
40,154
-9,846
-20% -$462K
BGMS
37
Bio Green Med Solution Inc
BGMS
$4.97M
$2.11M 0.53%
111
+5
+5% +$96.2K
NTLA icon
38
Intellia Therapeutics
NTLA
$1.56B
$2.01M 0.51%
15,000
+5,000
+50% +$757K
HARP
39
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.98M 0.5%
25,000
+20,000
+400% +$2.01M
GBT
40
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.91M 0.48%
75,000
+55,000
+275% +$1.62M
UTHR icon
41
United Therapeutics
UTHR
$22.6B
$1.85M 0.47%
+10,000
New +$1.97M
AFIB
42
DELISTED
Acutus Medical Inc
AFIB
$1.77M 0.45%
200,000
+120,000
+150% +$1.58M
ALDX icon
43
Aldeyra Therapeutics
ALDX
$104M
$1.74M 0.44%
197,759
-2,241
-1% -$20.6K
SEER icon
44
CALL
Seer Inc
SEER
$116M
$1.73M 0.44%
+50,000
New +$1.72M
HZNP
45
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.64M 0.41%
15,000
-10,000
-40% -$1.04M
MREO
46
Mereo BioPharma
MREO
$49.1M
$1.57M 0.4%
650,000
– –
BFLY icon
47
Butterfly Network
BFLY
$1.71B
$1.57M 0.4%
150,000
+50,000
+50% +$577K
SNCE
48
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.47M 0.37%
7,500
– –
SDGR icon
49
Schrodinger
SDGR
$1.13B
$1.37M 0.35%
25,000
– –
PCVX icon
50
Vaxcyte
PCVX
$8.02B
$1.27M 0.32%
50,000
– –
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Affinity Asset Advisors held 91 positions worth $396M, up 42% from $279M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Affinity Asset Advisors deployed $131M of net new capital in Q3 2021, opening 22 new positions and adding to 27 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 68% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Zentalis Pharmaceuticals, an estimated $3.74M trimmed.

  • Affinity Asset Advisors's largest Q3 2021 buy was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q3 2021, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q3 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $3.74M.
  • Affinity Asset Advisors fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $6.29M.
  • Affinity Asset Advisors's ten largest holdings make up 60% of its $396M portfolio in Q3 2021.
  • Affinity Asset Advisors opened 22 new positions and closed 18 in Q3 2021.
  • Affinity Asset Advisors's portfolio value rose 42% quarter-over-quarter to $396M.

Based on Affinity Asset Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.